KEDI Global Longevity Bio Index

The Annual Meeting of Stockholders is scheduled to be held virtually on May 15, 2026; a Low impact is estimated as annual meetings generally result in minimal immediate price volatility, scheduled.

Natera's Q1 2026 earnings release is expected.

Takeda is scheduled to announce its full-year earnings results for fiscal year 2025 (ending March 31, 2026) on May 13, 2026, expected. This major earnings release is estimated to have a >5% price impact.

Viatris is scheduled to report its first-quarter 2026 financial results on May 7, 2026; earnings releases are typically high-impact events, scheduled

The ex-dividend date for the 48.0p final dividend is May 7, 2026, with payment on June 18, 2026, likely causing a price adjustment of ≥1% scheduled.

Q1 2026 earnings release scheduled. Analysts forecast EPS around $0.77. Importance is an estimate based on the potential for significant stock movement following earnings announcements and guidance updates, scheduled.

Novo Nordisk is scheduled to release its financial results for the first quarter of 2026 on May 6, 2026, scheduled.

First-quarter 2026 financial results announcement on May 5, 2026; market impact is estimated as Medium based on historical earnings volatility, scheduled.

Leidos is scheduled to release its first quarter 2026 financial results before the market opens on 2026-05-05. A price impact of ≥5% is estimated based on historical earnings volatility, scheduled.

Pfizer is scheduled to report its Q1 2026 earnings on May 5, 2026. Analysts forecast EPS of $0.74 and revenue of $13.9 billion. Market impact is estimated at Medium (5%) as earnings reports typically drive significant volatility. This release is scheduled.

Revvity is scheduled to release its Q1 2026 financial results on May 5, 2026, with analysts forecasting an EPS of $1.02; earnings releases typically result in >5% price volatility, scheduled.

Moderna's Q1 2026 financial results and corporate update on May 1, 2026; Medium importance due to expected price impact ≥5%, scheduled.

First quarter 2026 earnings results and conference call, which is a significant market catalyst, scheduled.

Amgen is scheduled to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Earnings reports for major pharmaceutical companies typically result in price movements exceeding 5%.

Bristol-Myers Squibb is scheduled to announce its Q1 2026 financial results on April 30, 2026, before the market opens, followed by a conference call with the investment community; a Medium importance is estimated as earnings releases typically impact stock prices by at least 5%, scheduled.

Q1 2026 earnings release is scheduled. A medium impact is estimated as earnings reports typically drive significant price movement.

Merck is scheduled to announce its Q1 2026 financial results and hold a conference call with investors and analysts on April 30, 2026; analysts estimate a price impact of at least 5%, estimated.

First quarter 2026 earnings release is scheduled.

Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29; high impact expected as earnings often drive >10% volatility scheduled

AbbVie is scheduled to announce its first-quarter 2026 financial results on April 29, 2026; medium importance as quarterly results are estimated to have a price impact of 5% or more scheduled

First quarter 2026 earnings release on April 29, 2026, with medium importance estimated based on typical earnings-related price volatility, scheduled

Ionis Pharmaceuticals is scheduled to release its Q1 2026 financial results and provide a business update on April 29, 2026, via a live webcast; analysts estimate a 5% price impact based on historical volatility, scheduled.

Teva is scheduled to release its financial results for the first quarter of 2026, scheduled.

Q1 2026 earnings results and investor webcast are scheduled.

GSK Q1 2026 earnings release scheduled; low impact expected as it is a routine financial disclosure.

First quarter 2026 financial results are scheduled to be released on April 28, 2026. A Medium impact is estimated as earnings reports typically drive significant price volatility scheduled

First quarter 2026 earnings results scheduled to be released on 2026-04-23. Analysts estimate significant price volatility, so the impact is scheduled.

The 2026 Annual General Meeting is scheduled for April 23, 2026, to approve the final dividend and authorize share repurchases, likely resulting in a price impact of ≥1% scheduled.

Thermo Fisher Scientific is scheduled to release its financial results for the first quarter of 2026 before the market opens on Thursday, April 23, 2026, with a conference call at 8:30 a.m. ET scheduled. A low importance is assigned as the market impact will only be known upon the actual release.

First quarter 2026 financial results to be reported after market close on April 22, 2026, with analysts forecasting earnings of approximately $3.74 per share; a Medium impact is estimated as earnings reports typically drive significant price movement, forecasted.

Abbott is scheduled to announce its Q1 2026 financial results on April 16, 2026, before the market opens; analysts forecast EPS of $1.15 and revenue of $11.0 billion; earnings releases typically result in a ~5% price impact scheduled.

Ex-dividend date for the quarterly cash dividend of $0.07 per share on April 16, 2026; ex-dividend dates typically cause a minor price adjustment of ~1%.

GSK completed the acquisition of 35Pharma Inc. for $950 million on 2026-04-15, gaining its pulmonary hypertension drug candidate, HS235. The agreement was first announced on 2026-02-25.

Leidos announced a joint venture with investment firm Altaris, combining its Security Enterprise Solutions (SES) business with Altaris-owned Analogic on 2026-04-15; Leidos will retain a 41.5% stake in the new entity. A price impact of ≥5% is estimated due to the strategic restructuring of the security segment.

The ex-dividend date for AbbVie's quarterly cash dividend of $1.73 is scheduled for April 15, 2026; low importance as the dividend event is estimated to have a price impact of 1% or more scheduled

Novo Nordisk announced a strategic partnership with OpenAI on April 14, 2026, to integrate AI for drug discovery; high impact expected due to transformative potential.

Johnson & Johnson reported Q1 2026 sales of $24.1 billion and adjusted EPS of $2.70, beating analyst estimates, and raised its full-year guidance with a 3.1% dividend increase. Estimated 5% impact due to strong earnings and guidance; expected.

Barclays downgraded Revvity from 'Overweight' to 'Equal-Weight' and lowered its price target from $118.00 to $95.00 on April 14, 2026; this downgrade is estimated to result in a 5-10% price decline, estimated.

Received approval for $191 million in grant funding and up to $34 million annually in incentives from Virginia for a new manufacturing facility; a low market impact is estimated as the amount is small relative to the company's total valuation.

On April 14, 2026, it was reported that the US FDA refused to file partner Replimune's application for its drug RP1 in combination with Bristol Myers Squibb's Opdivo for advanced melanoma, citing concerns about the study design.

A new analysis of the SELECT trial published on April 14, 2026, showed semaglutide reduces cardiovascular events in patients with heart and fatty liver disease.

Regeneron and Telix Pharmaceuticals announced a strategic collaboration on 2026-04-13; the $2.1 billion deal is estimated to have a high market impact of >10%.

AbbVie is scheduled to announce an exclusive licensing agreement with Haisco Pharmaceutical for Nav1.8 inhibitors on April 13, 2026; medium importance as the deal is estimated to have a price impact of 5% or more scheduled

The U.S. FDA approved the first generic versions of AstraZeneca's blockbuster drug Farxiga for 14 companies; a medium market impact is estimated due to the significant revenue contribution of this product.

Announced positive results from the Phase 3 BRUIN CLL-322 trial, where Jaypirca in combination with venetoclax and rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia (CLL).

The U.S. FDA is expected to accept and grant Priority Review for the Biologics License Application for ifinatamab deruxtecan on April 13, 2026, with a decision date set for October 10, 2026; analysts estimate a price impact of at least 5%, estimated.

The European Commission approved Dupixent for pediatric CSU on 2026-04-13; this expansion is estimated to have a medium price impact of ~5%.

Highlighted positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, which uses Natera's Signatera MRD test for Large B-Cell Lymphoma.

The European Commission approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged two to eleven on 2026-04-13. Analysts estimate a Low impact as regulatory approvals for specific indications typically result in 1-5% price movements, so the impact is estimated.

Takeda and Veritas In Silico (VIS) announced the amicable termination of their joint research partnership to discover small molecules targeting mRNA, effective April 13, 2026. This termination is estimated to have a >1% price impact.

GSK announced positive results from its Phase I trial of mocertatug rezetecan (Mo-Rez) in gynaecological cancers on 2026-04-12, showing objective response rates of 62% in platinum-resistant ovarian cancer and 67% in advanced endometrial cancer.

AbbVie is scheduled to present Phase 2 data for ELAHERE® at the SGO Annual Meeting on April 12, 2026; low importance as the data presentation is estimated to have a price impact of 1% or more scheduled